- Agriculture
- Antibiotic/anti-viral
- Biologics
- Biomarkers
-
By Clinical Application
- Anesthesiology
- Blood & Lymphatic Disease
- CNS & Neurosciences
- Dermatology
- Diabetes, Metabolism, Endocrinology & Obesity
- Ear, Nose, & Throat
- Emergency Services
- Gastroenterology & Digestive Disease
- General & Plastic Surgery
- Health Education, Medical Training and Operations
- Heart and Vascular
- Immunology, Autoimmune & Inflammation
- Infectious Diseases
- Mental Health
- Multiple clinical applications
- Musculoskeletal Disorders, Orthopedics/Bone
- Nephrology/Renal
- Oncology
- Ophthalmology
- Orphan Diseases
- Pediatrics
- Physical Medicine & Rehabilitation
- Radiology
- Regenerative Medicine / Tissue Engineering
- Reproductive Health: Obstetrics & Gynecology
- Respiratory & Pulmonary
- Surgery
- Transplantation
- Urology
- Wound Healing
- COVID-19
- Creative Works
- Diagnostics
- Drug Delivery
- Drug screening and discovery
- Energy, Cleantech & Environmental
- Engineering & Physical Sciences
- Gene therapy
- Imaging
- Materials
- Medical Devices
- Nutraceuticals
- Other
- Research & Design Tools
- RNAi/siRNA
- Sensors & Controls
- Small molecules
- Software & Information Technology
- Stem Cells
- Vaccines
Chimeric AAV vectors enabling antibody evasion and redosing for cardiac gene therapy
Unmet Need Gene therapy using adeno-associated virus (AAV) vectors is severely limited by pre-existing immunity in 30–80% of adults and by the development of neutralizing antibodies after initial treatment, preventing redosing. There is a critical…
Rationally designed chimeric AAV capsids for enhanced immune evasion, cellular uptake, and transduction efficiency
Unmet Need Adeno-associated virus (AAV) vectors are a leading platform for in vivo gene therapy, yet their clinical potential is limited by key biological barriers. Pre-existing immunity to common AAV serotypes diminishes vector efficacy and…
Viral-mediated humanized mouse model for Parkinson’s disease
Unmet Need Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the midbrain and the accumulation of α-synuclein aggregates (Lewy bodies), leading to motor and cognitive impairments. PD…
A novel all-in-one AAV system for efficient epigenome editing in neurodegenerative diseases
Unmet Need Neurodegenerative diseases such as Alzheimer’s and Parkinson’s affect over 55 million people worldwide, with prevalence expected to double by 2050 due to aging populations. These conditions are progressive, debilitating, and currently have no…
Novel epigenome editors for multiplexed gene regulation
Unmet Need Epigenome editors activate or inhibit gene expression without modifying the underlying DNA sequence. Consequently, these editors can reversibly fine-tune gene expression without the risk of permanently altering the genome or off-target editing. Epigenome…
Toolkit to edit any gene with universal CRISPR/Cas9 vectors
Unmet Need Genetic editing with the CRISPR/Cas9 system has quickly become ubiquitous in biotechnology research. One common application is studying proteins by editing the genes that encode them. Proteins have numerous functions, acting as receptors,…
Novel Method for Creating and Modifying Stable Cell Lines for Enhanced Proteomic Analysis
Unmet Need Characterizing the composition and function of protein complexes can facilitate the understanding of key cellular processes. Indeed, the global proteomics market was estimated to be USD 25.9 billion in 2021. However, the analysis…
Methods and compositions to sense m6A RNA modifications using a genetically encoded sensor
Unmet Need Gene expression is highly regulated through the addition of chemical modifications to RNA molecules. One such modification is methylation of adenosine residues to form m6A, a modified nucleotide which is found in thousands…
Plasmids for the overexpression of GPCRs
Technology Duke inventors have generated four novel GPCR plasmids that can be used for the stable overexpression of several GPCRs: pcDNA3-Flag-β2AR pcDNA3-hAT1R (human) pcDNA3-HA-rATlaR (rat) pcDNA3-Flag-rATlaR (rat)
Plasmids for the expression of B-arrestins and GRKs
Technology Duke inventors have generated 12 novel plasmids that can be used for the expression of β-arrestins and GRKs: pCDNA3-βarrestin1-Flag pCDNA3-βarrestin2-Flag pGEX-5G/LIC-βarrestin1 pGEX-5G/LIC-βarrestin2 pGEX-4T1-βarrestin1 C-terminus pGEX-4T1-βarrestin2 C-terminus pRK5-bGRK2 pRK5-bGRK3 pRK5-bGRK4 pRK5-hGRK5 pRK5-hGRK6 pRK5-hGRK26caax
Plasmids with RNA aptamers to B-arrestin
Technology Duke inventors have created 10 novel plasmids which can be used for the production of RNA aptamers to β-arrestins through in vitro translation: pCR-TOPO-8R1-36 pCR-TOPO-8R2-1 pCR-TOPO-8R2-15 pCR-TOPO-8R2-16 pCR-TOPO-8R2-20 pCR-TOPO-8R2-21 pCR-TOPO-8R2-24 pCR-TOPO-11R2-5 pCR-TOPO-11R2-7 pCR-TOPO-11R2-15
Cell line expressing chimeric Tie2 receptors
Technology Duke inventors have generated a cell line that expresses chimeric Tie2 receptors. Specifically, NIH 3T3 cells were infected with retroviruses containing a plasmid that encoded the extracellular and transmembrain domains of the c-fms receptor…